Last reviewed · How we verify
NCT02692313: Epineprhine
Hypoglycemia Associated Autonomic Dysfunction Dose Response of Epinephrine
EARLY_PHASE1 trial testing Epinephrine in Diabetes Complications in 32 participants. Completed in 1 September 2025.
1 September 2025
Quick facts
| Lead sponsor | University of Maryland, Baltimore |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 1 June 2016 |
| Primary completion | 1 September 2025 |
| Estimated completion | 1 September 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Epinephrine (epinephrine) — full drug profile →
- Saline infusion — full drug profile →
Conditions studied
- Diabetes Complications — all drugs for Diabetes Complications →
Sponsor
University of Maryland, Baltimore
Who can join
Adults 18 to 55, any sex, with Diabetes Complications. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Flow mediated dilation (FMD) of the brachial artery
Time frame: From baseline (pre glucose clamp) to end of experiment (time 240 minutes- 2 hours post intervention (glucose clamp))
Measurements of FMD will be taken at baseline (pre intervention) and end of glucose clamp (post intervention) and the maximal % change determined
Sponsor's own description
Epinephrine is the principal physiologic defense against hypoglycemia in type 1 and longer duration type 2 DM. Despite this, it is unknown how epinephrine regulates in-vivo endothelial function and atherothrombotic balance in humans. The specific aim of our study will be to determine the dose response effects of the key ANS counterregulatory hormone epinephrine on endothelial function, fibrinolytic balance and pro-atherogenic inflammatory mechanisms in healthy humans.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02692313
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Epinephrine
Trials testing the same drug.
- NCT07144267 — Comparison of Milrinone and Epinephrine on TAPSE · NA · not yet recruiting
- NCT06284434 — Liposomal Bupivacaine Use in Alveolar Bone Graft Patients · Phase 3 · recruiting
- NCT06416969 — Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation · EARLY_PHASE1 · recruiting
- NCT05738148 — Vasopressin vs. Epinephrine During Neonatal Cardiopulmonary Resuscitation · Phase 1 · active not recruiting
- NCT06013150 — Study of Inhaled DMC-IH1 and Intramuscular (EpiPen®) Epinephrine in Healthy Male and Female Participants. · Phase 1 · completed
Other recruiting trials for Diabetes Complications
Currently open trials in the same condition.
- NCT07195045 — Thai PainPREDICT Validation Study · NA · recruiting
- NCT07212075 — Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups · recruiting
- NCT06674980 — Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DF · NA · recruiting
- NCT07250607 — Extreme Phenotypes to Identify Susceptibility of Patients Living With Type 2 to Diabetes Related Complications · active not recruiting
- NCT06520995 — Elderly Patients With Type 2 Diabetes and Cognitive Exercises · NA · recruiting
Other University of Maryland, Baltimore trials
Trials by the same sponsor.
- NCT07537413 — Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia · Phase 4 · not yet recruiting
- NCT07221799 — OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis · Phase 1 · not yet recruiting
- NCT07094672 — Development of an Opioid Withdrawal Clinical Outcome Assessment · not yet recruiting
- NCT06583239 — Hub-Based Engagement Navigator Service to Reduce CSC Disengagement · NA · not yet recruiting
- NCT07536412 — Decision Aid Efficacy in Low Risk Thyroid Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02692313 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Maryland, Baltimore
- Last refreshed: 30 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02692313.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing